1. Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies. (23rd August 2022) Authors: Freedman, Mark S.; Pozzilli, Carlo; Havrdova, Eva Kubala; Lemle, Alexandre; Burcklen, Michel; Larbalestier, Anna; Hennessy, Brian; Sidorenko, Tatiana; Vaclavkova, Andrea; Olsson, Tomas Journal: Neurology Issue: Volume 99:Number 8(2022) Page Start: e762 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Mitigation of Initial Cardiodynamic Effects of the S1P1 Receptor Modulator Ponesimod Using a Novel Up‐Titration Regimen. (30th September 2016) Authors: Juif, Pierre‐Eric; Hoch, Matthias; Vaclavkova, Andrea; Krause, Andreas; Bush, Jim; Dingemanse, Jasper Journal: Journal of clinical pharmacology Issue: Volume 57:Number 3(2017) Page Start: 401 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pharmacokinetic‐Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Issue 3 (30th January 2023) Authors: Valenzuela, Belén; Poggesi, Italo; Luyckx, Nicolas; Vaclavkova, Andrea; Pérez‐Ruixo, Juan José Journal: Clinical pharmacology & therapeutics Issue: Volume 113:Issue 3(2023) Page Start: 692 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗